Evaluation of long-term efficacy of disease-modifying agents in patients with relapsing-remitting multiple sclerosis

Anita Risonjić, Hana Smajlović, Anisa Šero, Ena Šaranović, Nudžejma Veladžić, Maida Rakanović-Todić, Lejla Burnazović-Ristić, Sanita Maleškić Kapo, Enra Suljić


Objective. Disease-modifying therapy (DMT) still remains a
fundamental treatment for relapsing-remitting multiple sclerosis.
However, data about their resudual effect and relapse severity
after the discontinuation of treatment remain scarce. The
objective of this study was to evaluate the presence of residual
effect of metenkefalin and tridecactide, as a novel disease-modifying
agent (DMT), in treatment of relapsing-remitting multiple
sclerosis (RRMS).
Materials and methods. A retrospective observational study
was conducted to examine number and severity of relapses in
a two-year period after the discontinuation of DMT. Data of
total of 40 patients were included in the study analysis. Of that
number, 32 received combination of metenkefalin and tridecactide,
while 8 patients received interferon-β–1b (IFN-β-1b). The
objective parameter for relapse severity was Expanded Disability
Status Scale (EDSS) score.
Results. 8 out of 40 patients who received DMT were hospitalized
for relapses in a two-year period after the end of treatment.
All of them after discountinuation of treatment with
combination of metenkefalin and tridecactide. The median age
of patients was 41.38±10.1 years (range from 26 to 60 years).
Two thirds of these patients (6 patients) had only one relapse.
The median time from the end of the treatment to relapse was
8.15±3.65 months (range from 1.5 from 14.7 months). The
median value of EDSS score during the relapses was 3.25 (3.0-
4.25) and it was significantly higher than the median value of
EDSS score at the end of metenkefalin and tridecactide treatment
[2.5(1.38-3.0)] (p=0.041; p>0.05).
Conclusion. The results of our study indicate some residual effect
of metenkefalin and tridecactide treatment on relapse rate
that should be further explored.
Keywords: multiple sclerosis, disease-modifying therapy, metenkefalin
and tridecactide, relapse

Full Text:



Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B,

Wiendl H, Kieseier BC. Optimizing therapy early in multiple

sclerosis: An evidence-based view. Mult Scler Relat Disord.

Sep;4(5):460-469. doi: 10.1016/j.msard.2015.07.007.

Epub 2015 Jul 17.

Farjam M, Zhang GX, Ciric B, Rostami A. Emerging immunopharmacological

targets in multiple sclerosis. J Neurol

Sci. 2015 Nov 15;358(1-2):22-30. doi: 10.1016/j.

jns.2015.09.346. Epub 2015 Sep 14.

Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik

T. Timing of high-efficacy therapy in relapsing-remitting

multiple sclerosis: A systematic review. Autoimmun

Rev. 2017 Jun;16(6):658-665. doi: 10.1016/j.autrev.

04.010. Epub 2017 Apr 17.

Alajbegovic A, Mulabegovic N, Suljic-Mehmedika E. Enkorten

– a new option in treatment of MS, Influcene on EDSS.

Poster. Farmacija doo. 2008.

Enkorten. Available at: http://oldwww.ccpit.org/Contents/



The Use of Disease-Modifying Therapies in Multiple Sclerosis:

Principles and Current Evidence A Consensus Paper by

the Multiple Sclerosis Coalition, Updated on March 2017.

Einarson TR, Bereza BG, Machado M. Comparative effectiveness

of interferons in relapsing–remitting multiple sclerosis:

a meta-analysis of real-world studies. Current Medical

Research and Opinion. 2017;33(3):579–593. doi:10.1080/


Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-

Guttman B. Interferon β for Multiple Sclerosis. Cold

Spring Harb Perspect Med. 2018 Jan 8. pii: a032003. doi:

1101/cshperspect.a032003. [Epub ahead of print]

Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM,

Liu S, Chapman RH, Kumar V, Carlson JJ. Disease-Modifying

Therapies for Relapsing-Remitting and Primary Progressive

Multiple Sclerosis: A Cost-Utility Analysis. CNS Drugs.

Aug 23. doi: 10.1007/s40263-018-0566-9. [Epub

ahead of print]

Pardo G and Jones DE: The sequence of disease-modifying

therapies in relapsing multiple sclerosis: safety and immunologic

considerations. J Neurol. 2017; 264(12): 2351–2374.

Published online 2017 Sep 6. doi: 10.1007/s00415-017-


Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat

D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A,

Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B,

Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche

J-P, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A,

Papeix C, Brochet B, Pelletier J, Lebru C, Club Francophone

de la Sclérose en Plaques Investigators: Switching From Natalizumab

to Fingolimod in Multiple Sclerosis: A French

Prospective Study. JAMA Neurol. 2014 Apr;71(4):436-41.

doi: 10.1001/jamaneurol.2013.6240.

Berger B, Baumgartner A, Rauer S, Mader I, Luetzen

N, Farenkopf U, Stich O: Severe Disease Reactivation in

Four Patients With Relapsing-Remitting Multiple Sclerosis

After Fingolimod Cessation. J Neuroimmunol. 2015 May

;282:118-22. doi: 10.1016/j.jneuroim.2015.03.022.

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D,

Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G,

Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano

M, Sormani MP, Durelli L: Treatment of Relapsing-Remitting

Multiple Sclerosis After 24 Doses of Natalizumab: Evidence

From an Italian Spontaneous, Prospective, and Observational

Study (The TY-STOP Study). JAMA Neurol. 2014

Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200

Galea I, Ward-Abel N, Heesen C. Relapse in multiple sclerosis.

BMJ. 2015;350:1765–1765. doi:10.1136/bmj.h1765


ICER-VAF-Update-Proposals-020117.pdf. Accessed 8 October

Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple

sclerosis are age- and time-dependent. J Neurol Neurosurg

Psychiatry 2008;79:1368-74.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M,

Sørensen PS, Sellebjerg F, Søndergaard HB. Smoking affects

the interferon beta treatment response in multiple

sclerosis. Neurology. 2018;90(7):e593-e600. doi: 10.1212/

WNL.0000000000004949. Epub 2018 Jan 17.


  • There are currently no refbacks.